Implementing Quality Measures for Inflammatory Bowel Disease

Current Gastroenterology Reports

Volumn 17, Issue 4, 2015, Pages

  Ahmed, Shahzad ^a   Siegel, Corey A ^b   Melmed, Gil Y ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Dartmouth Hitchcock Inflammatory Bowel Disease Center   (United States)

Author keywords

Crohn disease; Improvement; Inflammatory bowel disease; Quality; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; BIOLOGICAL PRODUCT; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

CLINICAL PATHWAY; CROHN DISEASE; DISEASE CONTROL; ELECTRONIC MEDICAL RECORD; GASTROINTESTINAL SURGERY; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; LENGTH OF STAY; MORTALITY; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PATIENT REFERRAL; PROFESSIONAL STANDARD; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TOTAL QUALITY MANAGEMENT; WORKFLOW; ALGORITHM; INFLAMMATORY BOWEL DISEASES; STANDARDS; TREATMENT OUTCOME; TRENDS;

ALGORITHMS; HUMANS; INFLAMMATORY BOWEL DISEASES; QUALITY IMPROVEMENT; QUALITY INDICATORS, HEALTH CARE; QUALITY OF HEALTH CARE; TREATMENT OUTCOME;

EID: 84924778132     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-015-0437-1     Document Type: Review

References (48)

1. Institute of Medicine. To err is human: building a safer health system. Washington: National Academies Press; 2000.
2. Institute of Medicine. Crossing the quality chasm: a new health system for the 21st century. Washington: National Academies Press; 2001.
3. Berwick DM, Nolan TW, Whittington J. The triple aim: care, health, and cost. Health Aff (Millwood). 2008;27:759–69.
4. de Jonge V, Sint Nicolaas J, van Leerdam ME, et al. Overview of the quality assurance movement in health care. Best Pract Res Clin Gastroenterol. 2011;25:337–47.
5. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–98.
6. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–13.
7. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961–72.
8. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607–21.
9. Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1622–32.
10. Berwick DM. Disseminating innovations in health care. Jama. 2003;289:1969–75.
11. Grol R, Wensing M. Implementation of quality assurance and medical audit: general practitioners’ perceived obstacles and requirements. Br J Gen Pract. 1995;45:548–52.
12. Wennberg JE. Unwarranted variations in healthcare delivery: implications for academic medical centres. BMJ. 2002;325:961–4.
13. Fisher ES, Wennberg DE, Stukel TA, et al. The implications of regional variations in medicare spending. Part 1: the content, quality, and accessibility of care. Ann Intern Med. 2003;138:273–87.
14. Fisher ES, Wennberg DE, Stukel TA, et al. The implications of regional variations in medicare spending. Part 2: health outcomes and satisfaction with care. Ann Intern Med. 2003;138:288–98.
15. Reddy SI, Friedman S, Telford JJ, et al. Are patients with inflammatory bowel disease receiving optimal care? Am J Gastroenterol. 2005;100:1357–61.
16. Esrailian E, Spiegel BM, Targownik LE, et al. Differences in the management of Crohn’s disease among experts and community providers, based on a national survey of sample case vignettes. Aliment Pharmacol Ther. 2007;26:1005–18.
17. Altschuler A, Collins B, Lewis JD, et al. Gastroenterologists’ attitudes and self-reported practices regarding inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:992–9.
18. Spiegel BM, Ho W, Esrailian E, et al. Controversies in ulcerative colitis: a survey comparing decision making of experts versus community gastroenterologists. Clin Gastroenterol Hepatol 2009;7:168–74, 174 e1.
19. Kornbluth A, Hayes M, Feldman S, et al. Do guidelines matter? Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines’ criteria. Am J Gastroenterol. 2006;101:1546–50.
20. Kottachchi D, Yung D, Marshall JK. Adherence to guidelines for surveillance colonoscopy in patients with ulcerative colitis at a Canadian quaternary care hospital. Can J Gastroenterol. 2009;23:613–7.
21. James BC, Savitz LA. How Intermountain trimmed health care costs through robust quality improvement efforts. Health Aff (Millwood). 2011;30:1185–91.
22. Bradford K, Melmed GY, Fleshner P, et al. Significant variation in recommendation of care for women of reproductive age with ulcerative colitis postileal pouch-anal anastomosis. Dig Dis Sci. 2014;59:1115–20.
23. Kaplan GG, McCarthy EP, Ayanian JZ, et al. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology. 2008;134:680–7.
24. Ananthakrishnan AN, McGinley EL, Binion DG. Does it matter where you are hospitalized for inflammatory bowel disease? A nationwide analysis of hospital volume. Am J Gastroenterol. 2008;103:2789–98.
25. Eliakim R, Yassin K, Shlomi I, et al. A novel diagnostic tool for detecting oesophageal pathology: the PillCam oesophageal video capsule. Aliment Pharmacol Ther. 2004;20:1083–9.
26. UK IBD Audit. Model action plan for IBD Services. 2006 < url: https://www.rcplondon.ac.uk/sites/default/files/uk_ibd_audit_2006_national_report_appendices_print_copy.pdf. Accessed 11 Jan 2014.
27. Services CfmaM. Physician Quality Reporting System (PQRS) measures list. 2013.
28. Fireman Z, Paz, D. Capsule endoscopy: improving the transit time and the image view (abstract). Digestive Disease Week 2004 2004;abstract id. 101871.
29. Melmed GY, Siegel CA, Spiegel BM, et al. Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis. 2013;19:662–8. This article describes the methodology of development of quality indicators for adults with IBD.
30. Fireman Z, Eliakim R, Adler S, et al. Capsule endoscopy in real life: a four-centre experience of 160 consecutive patients in Israel. Eur J Gastroenterol Hepatol. 2004;16:927–31.
31. IHI. The Breakthrough Series: IHI’s Collaborative model for achieving breakthrough improvement. IHI Innovation Series white paper. 2003.
32. Miller MR, Niedner MF, Huskins WC, et al. Reducing PICU central line-associated bloodstream infections: 3-year results. Pediatrics. 2011;128:e1077–83.
33. Neu AM, Miller MR, Stuart J, et al. Design of the standardizing care to improve outcomes in pediatric end stage renal disease collaborative. Pediatr Nephrol. 2014;29(9):1477–84.
34. Schechter MS, Fink AK, Homa K, et al. The cystic fibrosis foundation patient registry as a tool for use in quality improvement. BMJ Qual Saf. 2014;23 Suppl 1:i9–14.
35. O’Connor GT, Plume SK, Olmstead EM, The Northern New England Cardiovascular Disease Study Group, et al. A regional intervention to improve the hospital mortality associated with coronary artery bypass graft surgery. Jama. 1996;275:841–6.
36. Farias M, Jenkins K, Lock J, et al. Standardized Clinical Assessment and Management Plans (SCAMPs) provide a better alternative to clinical practice guidelines. Health Aff (Millwood). 2013;32:911–20.
37. Crandall WV, Boyle BM, Colletti RB, et al. Development of process and outcome measures for improvement: lessons learned in a quality improvement collaborative for pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:2184–91. This paper describes efforts of the ImproveCareNow network to develop quality improvement measures for pediatric IBD.
38. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368–77.
39. Yealy DM, Kellum JA, Huang DT, et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med. 2014;370:1683–93.
40. King KM, Adams BD, ACP Journal Club. In septic shock, early goal-directed or standard protocol-based therapy did not reduce mortality. Ann Intern Med. 2014;160:Jc9.
41. Koves IH, Leu MG, Spencer S, et al. Improving care for pediatric diabetic ketoacidosis. Pediatrics. 2014;134(3):e848–56.
42. Blackwood B, Alderdice F, Burns KE, et al. Protocolized versus non-protocolized weaning for reducing the duration of mechanical ventilation in critically ill adult patients. Cochrane Database Syst Rev. 2010;12(5), CD006904.
43. Barnes AJ, Unruh L, Chukmaitov A, et al. Accountable care organizations in the USA: types, developments and challenges. Health Policy. 2014;118(1):1–7.
44. Sandborn WJ. Crohn’s disease evaluation and treatment: clinical decision tool. Gastroenterology. 2014;147:702–5. This framework provides strategies for risk stratification and treatment of patients with Crohn’s Disease with the goal of achieving resolution of mucosal inflammation. This goal is geared towards ultimately preventing progression of disease activity with the associated increased morbidity and mortality.
45. D’Haens GR. Top-down therapy for IBD: rationale and requisite evidence. Nat Rev Gastroenterol Hepatol. 2010;7:86–92.
46. D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008;371:660–7.
47. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–95.
48. Khanna RLB, Bressler B, Zou G, Stitt L, Greenberg GR, Panaccione R, et al. Early combined immunosuppression for the management of Crohn’s disease: a community-based cluster randomized trial. J Crohn’s Colitis. 2014;8:S2–3. This study demonstrated successful implementation of a “top down” treatment algorithm in community gastroenterology practice. The algorithm was associated with decreased hospitalization, complications and surgeries in comparison to conventional management.